Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Liqmeds Worldwide Limited maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are handled by 2 distinct examiners, meaning each pending action is being reviewed by a different examiner. Prosecution activity is distributed across 2 distinct art units, which indicates that the company's biotechnology innovations are being reviewed by two specialized groups within the USPTO.
WELLS, LAUREN QUINLAN is the busiest examiner, currently overseeing 1 busiest examiner pending office action. This matching number between 2 pending office actions and 2 distinct examiners shows a decentralized prosecution effort. With 2 pending office actions and 2 distinct examiners involved, the portfolio is managed across multiple USPTO personnel. WELLS, LAUREN QUINLAN handles 1 busiest examiner pending office action, which is the same number of actions assigned to the other examiner in this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19635110 | PHARMACEUTICAL SOLUTION FOR ORAL DOSAGE | WELLS, LAUREN QUINLAN | — |
| 19015873 | Mycophenolate Oral Suspension | TRUONG, QUANGLONG N | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19635110 | PHARMACEUTICAL SOLUTION FOR ORAL DOSAGE | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | — | Pending | Mar 31, 2026 |
| 19015873 | Mycophenolate Oral Suspension | TRUONG, QUANGLONG N | 1615 | §103DP | Non-Final OA | — | Pending | Jan 10, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLiqmeds Worldwide Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Lauren Quinlan Wells has the most, with 1 of Liqmeds Worldwide Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
